Wat beteken "Clear"?
Die dier dra nie die mutasie nie. Dit sal nie die siekte ontwikkel nie en sal dit nie deurgee nie.
The DNA test for Gangliosidosis Type 2 Variant 0 (GM2-var0) in Shiba Inu dogs is essential for early detection of this rare genetic disorder. GM2-var0 affects the nervous system, leading to severe neurological symptoms and reduced quality of life. By identifying carriers and affected dogs through this DNA test, breeders can make informed decisions to prevent the spread of the disease. Early diagnosis allows for better management and care of affected Shiba Inus. This genetic screening supports responsible breeding practices and promotes healthier future generations. If you own a Shiba Inu, consider the GM2-var0 DNA test to safeguard your dog's health. Reliable testing helps protect this beloved breed from hereditary gangliosidosis.
Sandhoff
The DNA test for Gangliosidosis Type 2 Variant 0 (GM2-var0) in Shiba Inu detects a genetic mutation responsible for a rare lysosomal storage disorder. This condition leads to the accumulation of harmful substances in nerve cells, causing neurological symptoms and progressive decline. Early identification through testing helps breeders avoid producing affected puppies. Carriers show no symptoms but can pass the mutation to offspring. Genetic screening is essential for maintaining the health and longevity of the Shiba Inu breed.
Hierdie DNS-toets is ingesluit vanaf ons pak Basic — en is ook deel van die pakke Basic, Standard, Advanced, Complete.
Bekyk DNA-toetspakkette →Gangliosidosis Type 2 Variant 0 (GM2-var0) is a genetic disorder affecting the Shiba Inu breed, characterized by a deficiency of the enzyme hexosaminidase A (Hex-A). This enzyme plays a crucial role in the breakdown of certain lipids in the body. When Hex-A is deficient, gangliosides, which are complex lipids found in nerve cells, accumulate abnormally, leading to neurological issues and other systemic problems.
Dogs affected by GM2-var0 may exhibit a range of clinical symptoms that typically manifest in early to middle life. Common signs include neurological dysfunction, which can present as loss of coordination, muscle weakness, and behavioral changes. Affected dogs may also show developmental delays or regression, difficulty in movement, and, in some cases, seizures. The severity and progression of symptoms may vary significantly among individual dogs.
The pathophysiology of Gangliosidosis Type 2 Variant 0 involves the accumulation of GM2 gangliosides in the central nervous system and other tissues due to the impaired activity of the Hex-A enzyme. This accumulation leads to cellular damage and dysfunction, particularly in neurons. As a result, the myelin sheath, which insulates nerve fibers and facilitates efficient signal transmission, may also be affected, further exacerbating neurological deficits.
Diagnosis of GM2-var0 is achieved through genetic testing that identifies mutations in the HEXA gene responsible for the production of the Hex-A enzyme. Early diagnosis is critical, as it allows for better management of the condition and helps owners make informed decisions regarding the care of their pets. Genetic testing can also provide valuable information for breeders, helping to reduce the incidence of this condition in future generations.
While there is currently no cure for GM2-var0, supportive care can help improve the quality of life for affected dogs. This may include physical therapy, nutritional support, and medications to manage symptoms such as seizures or pain. Regular veterinary check-ups are essential to monitor the progression of the disease and adjust care as needed. Owners are encouraged to provide a stable and loving environment to enhance their pet's well-being.
Gangliosidosis Type 2 Variant 0 is a serious genetic condition in Shiba Inu that has significant implications for affected dogs and their owners. Awareness and understanding of GM2-var0 can lead to early detection and better management strategies, ultimately improving the lives of dogs diagnosed with this disorder. Responsible breeding practices, including genetic testing, can help mitigate the prevalence of GM2-var0 in the Shiba Inu population.
Die dier dra nie die mutasie nie. Dit sal nie die siekte ontwikkel nie en sal dit nie deurgee nie.
Nee. Die dier is oor die algemeen gesond, maar kan die mutasie na sy oordra nageslag.
Dit dra twee gemuteerde kopieë. Kliniese tekens word verwag afhangende van die siekte. Dit moet nie geteel word nie.
Sommige siektes is geslagsgekoppel, so hul uitdrukking wissel na gelang van die dier se geslag.
This DNA test detects the mutation associated with Gangliosidosis Type 2 Variant 0 In Shiba Inu (GM2-var0-SI) in order to identify clear, carrier, or at-risk animals.
DNS-toetse help telers om veiliger parings te beplan en die risiko te verminder dat die mutasie na die nageslag oorgedra word.
Die oorerwingsmodus wat vir hierdie toets gerapporteer word, is outosomaal resessief.
This test analyses the mutation HEXB c.849_851del CCT.
Nie noodwendig nie. Interpretasie hang af van die oorerwingspatroon en die gevolglike genotipe.
Jou privaatheid, jou keuse
Ons gebruik noodsaaklike koekies om die webwerf te bestuur. Opsionele webkoekies (soos verskaffers van ingebedde inhoud) is by verstek gedeaktiveer en word slegs geaktiveer as jy saamstem. Jy kan enige tyd jou keuse verander deur die "Koekies"-knoppie te gebruik.
Vereis vir kernkenmerke en sekuriteit. Altyd geaktiveer.
Verbeter kenmerke soos voorkeurbesparing of nie-reklame-insluitsels.
Help ons om werfgebruik te verstaan. By verstek gedeaktiveer.
Advertensies/nasporing oor werwe heen (sommige video-/kaarte-inbedings). By verstek gedeaktiveer.